These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8165904)

  • 1. Dose-related protective efficacy of immunoglobulins in experimentally induced group B streptococcal infection.
    Iguchi K; Inoue S
    Acta Paediatr Jpn; 1994 Feb; 36(1):25-9. PubMed ID: 8165904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High intravenous doses of human immune globulin suppress neonatal group B streptococcal immunity in rats.
    Weisman LE; Lorenzetti PM
    J Pediatr; 1989 Sep; 115(3):445-50. PubMed ID: 2671331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models.
    Givner LB
    Pediatrics; 1990 Dec; 86(6):955-62. PubMed ID: 2123536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates.
    Weisman LE; Anthony BF; Hemming VG; Fischer GW
    J Pediatr; 1993 Jun; 122(6):929-37. PubMed ID: 8501574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced killing of group B streptococci in vitro by penicillin and opsonophagocytosis with intravenous immunoglobulin.
    Miller PS; Schauf V; Salo RJ
    J Infect Dis; 1990 Jun; 161(6):1225-30. PubMed ID: 2111840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characteristics of a modified immunoglobulin preparation for intravenous administration: summary of studies of opsonic and protective activity against group B streptococci.
    Fischer GW; Wilson SR; Hunter KW
    J Clin Immunol; 1982 Apr; 2(2 Suppl):31S-35S. PubMed ID: 7045156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directed immune globulin for the prevention or treatment of neonatal group B streptococcal infections: a review.
    Fischer GW; Weisman LE; Hemming VG
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S92-7. PubMed ID: 1728993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin therapy of neonatal group B streptococcal infections: an overview.
    Fischer GW
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S13-6. PubMed ID: 3041355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections.
    Basma H; Norrby-Teglund A; McGeer A; Low DE; El-Ahmedy O; Dale JB; Schwartz B; Kotb M
    Infect Immun; 1998 May; 66(5):2279-83. PubMed ID: 9573118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone effects on group B streptococcal infection in newborn rats.
    Tran TV; Weisman LE
    Pediatr Infect Dis J; 2004 Jan; 23(1):47-52. PubMed ID: 14743046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential use of intravenous immune globulin for group B streptococcal infection.
    Baker CJ; Noya FJ
    Rev Infect Dis; 1990; 12 Suppl 4():S476-82. PubMed ID: 2194272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified human immune serum globulin for intravenous administration: in vitro opsonic activity and in vivo protection against group B streptococcal disease in suckling rats.
    Fischer GW; Hunter KW; Wilson SR
    Acta Paediatr Scand; 1982 Jul; 71(4):639-44. PubMed ID: 6753478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci.
    Hill HR; Gonzales LA; Knappe WA; Fischer GW; Kelsey DK; Raff HV
    J Infect Dis; 1991 Apr; 163(4):792-8. PubMed ID: 2010632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease.
    Hill HR; Kelsey DK; Gonzales LA; Raff HV
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S87-91. PubMed ID: 1728992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyvalent group B streptococcal immune globulin for intravenous administration: overview.
    Fischer GW; Hemming VG; Gloser HP; Bachmayer H; von Pilar CE; Wilson SR; Baron PA
    Rev Infect Dis; 1990; 12 Suppl 4():S483-9; discussion S489-91. PubMed ID: 2194273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous gamma globulin as adjunct therapy for severe group B streptococcal disease in the newborn.
    Friedman CA; Wender DF; Temple DM; Rawson JE
    Am J Perinatol; 1990 Jan; 7(1):1-4. PubMed ID: 2104748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant human granulocyte colony-stimulating factor administration in normal and experimentally infected newborn rats.
    Iguchi K; Inoue S; Kumar A
    Exp Hematol; 1991 Jun; 19(5):352-8. PubMed ID: 1709109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin in neonatal group B streptococcal disease. Pharmacokinetic and safety studies in monkeys and humans.
    Fischer GW; Weisman LB; Hemming VG; London WT; Hunter KW; Bosworth JM; Sever JL; Wilson SR; Curfman BL
    Am J Med; 1984 Mar; 76(3A):117-23. PubMed ID: 6424443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opsonic activity of commercially available standard intravenous immunoglobulin preparations.
    Weisman LE; Cruess DF; Fischer GW
    Pediatr Infect Dis J; 1994 Dec; 13(12):1122-5. PubMed ID: 7892082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.
    Sriskandan S; Ferguson M; Elliot V; Faulkner L; Cohen J
    J Antimicrob Chemother; 2006 Jul; 58(1):117-24. PubMed ID: 16670109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.